Toronto Dominion Bank
ABCL icon

Toronto Dominion Bank’s AbCellera Biologics ABCL Stock Holding History

Toronto Dominion Bank’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,500
Closed -$15K – 1414
2022
Q4 		$15K Hold
1,500
– – ﹤0.01% 1373
2022
Q3 		$15K Buy
+1,500
New +$16.5K ﹤0.01% 1432

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Toronto Dominion Bank's ABCL Position: Q4 2023 in Review

Toronto Dominion Bank sold out of AbCellera Biologics (ABCL) in Q4 2023, closing a stake of 175 shares — an estimated $811 sold.

Toronto Dominion Bank first reported a position in ABCL in Q3 2022 and held it in 5 quarters. The position peaked at $12K in Q4 2022. 142 funds tracked by Wall St. Rank hold ABCL as of Q4 2023.

  • Toronto Dominion Bank reported no remaining AbCellera Biologics position as of Q4 2023 after selling out during the quarter.
  • Toronto Dominion Bank sold 175 AbCellera Biologics shares in Q4 2023, an estimated $811.
  • Toronto Dominion Bank first reported a position in AbCellera Biologics in Q3 2022 and held it in 5 quarters.
  • Toronto Dominion Bank's AbCellera Biologics position peaked at $12K in Q4 2022.
  • 142 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2023.

Based on Toronto Dominion Bank's 13F filing for Q4 2023, filed 13 Feb 2024.